GPCR Archives

In Depth 20 Nov 2024

Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024

The hypoparathyroidism treatment space has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials.

November 20, 2024 - 8 minutesmins - By Roohi Mariam Peter

Best in Biotech 29 Oct 2024

GPCR therapies: Eight promising biotechs hacking the cell signaling pathway

In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.

October 29, 2024 - 11 minutesmins - By Roohi Mariam Peter

In Depth 12 Sep 2024

New treatments being developed for schizophrenia

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

September 12, 2024

More News! 26 Jul 2024

Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies

Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round.

July 26, 2024 - 8 minutesmins - By Jules Adam

News and Trends 3 Mar 2023

Lilly to develop Confo pain drug

Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Antiverse identifies therapeutic antibodies targeting GPCRs

Antiverse Ltd has announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. Antiverse, which was featured as one of our five Welsh biotech startups making waves in 2023, also announced it has raised $3 million funding, which will enable in-house development of the […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics

Our Beyond Biotech podcast 34 guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president and CSO of GPCR Therapeutics; and Larry A Couture, CEO of Orbsen Therapeutics. GPCR Therapeutics launches multiple myeloma trial GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, recently started […]

February 17, 2023

News and Trends 16 Feb 2023

Maxion Therapeutics raises $16M to target GPCRs

Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors (GPCRs) via Maxion’s proprietary, patent-protected KnotBody platform. Ion channels and GPCRs are critical cell surface proteins involved in a wide range of previously untreatable or […]

February 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Feb 2023

Orbit Discovery and Endevica Bio to develop cachexia therapeutics

Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. Endevica creates first-in-class therapeutics for cachexia caused by cancer and other chronic conditions. Its lead compound has proven to be safe and well-tolerated in phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

GPCR Therapeutics launches multiple myeloma trial

GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has started its phase 2 trial in the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers. This randomized, open-label phase 2 study assesses the efficacy […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, U.K., and KU Leuven, Belgium. Sosei Heptares focuses on G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development. The focus of the agreements is to apply the innovative technologies and research […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

More News! 9 Nov 2022

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way

PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […]

November 9, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GPCR

Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024

GPCR therapies: Eight promising biotechs hacking the cell signaling pathway

New treatments being developed for schizophrenia

Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies

Lilly to develop Confo pain drug

Antiverse identifies therapeutic antibodies targeting GPCRs

Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics

Maxion Therapeutics raises $16M to target GPCRs

Orbit Discovery and Endevica Bio to develop cachexia therapeutics

GPCR Therapeutics launches multiple myeloma trial

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!